Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
26 November 2021 | Story Lacea Loader | Photo Sonia Small (Kaleidoscope Studios)
Prof Philippe Burger
Prof Philippe Burger.

The Council of the University of the Free State (UFS) approved the appointment of Prof Philippe Burger as Dean of the Faculty of Economic and Management Sciences for a five-year term during its quarterly virtual meeting on 26 November 2021. 

He is Pro-Vice-Chancellor: Poverty, Inequality and Economic Development, as well as Vice-Dean (Strategic Projects) of the Faculty of Economic and Management Sciences, and Professor of Economics at the UFS. 

Extensive experience

Prof Burger was a 2016/17 Fulbright exchange scholar at the Center for Sustainable Development, Earth Institute, Columbia University in the United States, with Prof Jeffrey Sachs as his Fulbright host, where he wrote a book titled Getting it right: a new economy for South Africa. The book was launched, with presentations at the International Monetary Fund (IMF), World Bank, and RAND Corporation in Washington DC, among others. In addition, he is a member of the Fiscal Policy and Financial Markets Task Team of the Lancet Commission on COVID-19. Co-chaired by the Head of the IMF’s Department of Fiscal Affairs and a former Minister of Finance of Chile, the task team of 11 members comprises economists from across the world, including two Nobel prize winners. 

From September 2012 to October 2014, Prof Burger was President of the Economic Society of South Africa. His publications include three more books and numerous academic articles on fiscal rules and fiscal sustainability, public-private partnerships, and macroeconomic and economic development policy. Together with IMF staff, he co-authored two IMF working papers. In 2009, the IMF invited him to spend a month at the IMF as a visiting scholar in the Fiscal Affairs Department (FAD), researching public-private partnerships and the Global Financial Crisis. For two months each in 2007, 2010, and 2012, he was seconded to the Organisation for Economic Co-operation and Development (OECD) in Paris, France, to work on public-private partnerships and capital budgeting, while in October 2011 he joined an OECD mission to Indonesia to conduct a regulatory review of Indonesia. 

Prof Burger was a member of the Panel of Experts of the South African National Treasury, in which capacity he co-authored a 20-year review of South African fiscal policy since 1994. From 2013 to 2018, he was a member of the South African Statistics Council, which oversees the work of Statistics South Africa. From 1 February 2018 to 31 January 2019, he acted as dean of the Faculty of Economic and Management Sciences at the UFS, and from 2002 to 2019 he was Head of the UFS Department of Economics. 

“With more than 27 years of experience in the higher-education sector, Prof Burger will bring a wealth of expertise, extensive networks, and partnerships, nationally and abroad, to the Faculty of Economic and Management Sciences and the UFS. His experience in the positions held at the university, as well as his extensive knowledge and understanding of the South African and global economy, places him in good standing to lead the faculty to be a formidable and impactful academic force nationally and abroad,” said Prof Francis Petersen, UFS Rector and Vice-Chancellor. 

“Prof Burger has the competencies required as dean of the Faculty of Economic and Management Sciences, leading it to exploit opportunities and deal with the challenges that the rapidly changing world presents to the UFS,” said Prof Petersen.  

Vision for the faculty

In response to his appointment, Prof Burger said, “I am humbled by this appointment and look forward to taking on this wonderful challenge. The faculty has a strong team of academics and administrative staff. With this team, I know we will create wonderful pathways for our students into the future and into the complex world of work. I also look forward to strengthening our research position and building the faculty as a nationally and internationally recognised research-strong faculty, as well as a faculty with a very strong Global South presence.”

Prof Burger succeeds the current Dean, Prof Hendri Kroukamp, who will be retiring at the end of February 2022.  

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept